Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome

A prospective, multi-center, follow-up study

Francesco Carubbi, Paola Cipriani, Alessandra Marrelli, Paola D. Benedetto, Piero Ruscitti, Onorina Berardicurti, Ilenia Pantano, Vasiliki Liakouli, Saverio Alvaro, Alessia Alunno, Antonio Manzo, Francesco Ciccia, Roberto Gerli, Giovanni Triolo, Roberto Giacomelli

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Introduction: Primary Sjögren's syndrome (pSS) is an autoimmune disorder affecting exocrine glands; however, a subgroup of pSS patients experience systemic extra-glandular involvement leading to a worsening of disease prognosis. Current therapeutic options are mainly empiric and often translated by other autoimmune diseases. In the last few years growing evidence suggests that B-cell depletion by rituximab (RTX) is effective also in pSS. Patients with early active disease appear to be those who could benefit the most from RTX. The aim of this study was to investigate the efficacy and safety of RTX in comparison to disease modifying anti-rheumatic drugs (DMARDs) in early active pSS patients. Methods: Forty-one patients with early pSS and active disease (EULAR Sjogren's syndrome disease activity index, ESSDAI ≥ 6) were enrolled in the study. Patients were treated with either RTX or DMARDs in two different Rheumatology centers and followed up for 120 weeks. Clinical assessment was performed by ESSDAI every 12 weeks up to week 120 and by self-reported global disease activity pain, sicca symptoms and fatigue on visual analogic scales, unstimulated saliva flow and Schirmer's I test at week 12, 24, 48, 72, 96, and 120. Laboratory assessment was performed every 12 weeks to week 120. Two labial minor salivary gland (MSG) biopsies were obtained from all patients at the time of inclusion in the study and at week 120.Results: Our study demonstrated that RTX treatment results in a faster and more pronounced decrease of ESSDAI and other clinical parameters compared to DMARDs treatment. No adverse events were reported in the two groups. We also observed that RTX is able to reduce glandular infiltrate, interfere with B/T compartmentalization and consequently with the formation of ectopic lymphoid structures and germinal center-like structures in pSS-MSGs. Conclusions: To our knowledge, this is the first study performed in a large cohort of early active pSS patients for a period of 120 weeks. We showed that RTX is a safe and effective agent to be employed in pSS patients with systemic, extra-glandular involvement. Furthermore, our data on pSS-MSGs provide additional biological basis to employ RTX in this disease.

Original languageEnglish
Article numberR172
JournalArthritis Research and Therapy
Volume15
Issue number5
DOIs
Publication statusPublished - Oct 30 2013

Fingerprint

Safety
Antirheumatic Agents
Sodium Glutamate
Therapeutics
Asthenopia
Exocrine Glands
Minor Salivary Glands
Rituximab
Germinal Center
Sjogren's Syndrome
Rheumatology
Lip
Saliva
Autoimmune Diseases
B-Lymphocytes
Biopsy
Pain

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Carubbi, F., Cipriani, P., Marrelli, A., Benedetto, P. D., Ruscitti, P., Berardicurti, O., ... Giacomelli, R. (2013). Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: A prospective, multi-center, follow-up study. Arthritis Research and Therapy, 15(5), [R172]. https://doi.org/10.1186/ar4359

Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome : A prospective, multi-center, follow-up study. / Carubbi, Francesco; Cipriani, Paola; Marrelli, Alessandra; Benedetto, Paola D.; Ruscitti, Piero; Berardicurti, Onorina; Pantano, Ilenia; Liakouli, Vasiliki; Alvaro, Saverio; Alunno, Alessia; Manzo, Antonio; Ciccia, Francesco; Gerli, Roberto; Triolo, Giovanni; Giacomelli, Roberto.

In: Arthritis Research and Therapy, Vol. 15, No. 5, R172, 30.10.2013.

Research output: Contribution to journalArticle

Carubbi, F, Cipriani, P, Marrelli, A, Benedetto, PD, Ruscitti, P, Berardicurti, O, Pantano, I, Liakouli, V, Alvaro, S, Alunno, A, Manzo, A, Ciccia, F, Gerli, R, Triolo, G & Giacomelli, R 2013, 'Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: A prospective, multi-center, follow-up study', Arthritis Research and Therapy, vol. 15, no. 5, R172. https://doi.org/10.1186/ar4359
Carubbi, Francesco ; Cipriani, Paola ; Marrelli, Alessandra ; Benedetto, Paola D. ; Ruscitti, Piero ; Berardicurti, Onorina ; Pantano, Ilenia ; Liakouli, Vasiliki ; Alvaro, Saverio ; Alunno, Alessia ; Manzo, Antonio ; Ciccia, Francesco ; Gerli, Roberto ; Triolo, Giovanni ; Giacomelli, Roberto. / Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome : A prospective, multi-center, follow-up study. In: Arthritis Research and Therapy. 2013 ; Vol. 15, No. 5.
@article{52207a246b274fd4ba3aedefde8f2d3f,
title = "Efficacy and safety of rituximab treatment in early primary Sj{\"o}gren's syndrome: A prospective, multi-center, follow-up study",
abstract = "Introduction: Primary Sj{\"o}gren's syndrome (pSS) is an autoimmune disorder affecting exocrine glands; however, a subgroup of pSS patients experience systemic extra-glandular involvement leading to a worsening of disease prognosis. Current therapeutic options are mainly empiric and often translated by other autoimmune diseases. In the last few years growing evidence suggests that B-cell depletion by rituximab (RTX) is effective also in pSS. Patients with early active disease appear to be those who could benefit the most from RTX. The aim of this study was to investigate the efficacy and safety of RTX in comparison to disease modifying anti-rheumatic drugs (DMARDs) in early active pSS patients. Methods: Forty-one patients with early pSS and active disease (EULAR Sjogren's syndrome disease activity index, ESSDAI ≥ 6) were enrolled in the study. Patients were treated with either RTX or DMARDs in two different Rheumatology centers and followed up for 120 weeks. Clinical assessment was performed by ESSDAI every 12 weeks up to week 120 and by self-reported global disease activity pain, sicca symptoms and fatigue on visual analogic scales, unstimulated saliva flow and Schirmer's I test at week 12, 24, 48, 72, 96, and 120. Laboratory assessment was performed every 12 weeks to week 120. Two labial minor salivary gland (MSG) biopsies were obtained from all patients at the time of inclusion in the study and at week 120.Results: Our study demonstrated that RTX treatment results in a faster and more pronounced decrease of ESSDAI and other clinical parameters compared to DMARDs treatment. No adverse events were reported in the two groups. We also observed that RTX is able to reduce glandular infiltrate, interfere with B/T compartmentalization and consequently with the formation of ectopic lymphoid structures and germinal center-like structures in pSS-MSGs. Conclusions: To our knowledge, this is the first study performed in a large cohort of early active pSS patients for a period of 120 weeks. We showed that RTX is a safe and effective agent to be employed in pSS patients with systemic, extra-glandular involvement. Furthermore, our data on pSS-MSGs provide additional biological basis to employ RTX in this disease.",
author = "Francesco Carubbi and Paola Cipriani and Alessandra Marrelli and Benedetto, {Paola D.} and Piero Ruscitti and Onorina Berardicurti and Ilenia Pantano and Vasiliki Liakouli and Saverio Alvaro and Alessia Alunno and Antonio Manzo and Francesco Ciccia and Roberto Gerli and Giovanni Triolo and Roberto Giacomelli",
year = "2013",
month = "10",
day = "30",
doi = "10.1186/ar4359",
language = "English",
volume = "15",
journal = "Arthritis Research and Therapy",
issn = "1478-6354",
publisher = "BioMed Central",
number = "5",

}

TY - JOUR

T1 - Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome

T2 - A prospective, multi-center, follow-up study

AU - Carubbi, Francesco

AU - Cipriani, Paola

AU - Marrelli, Alessandra

AU - Benedetto, Paola D.

AU - Ruscitti, Piero

AU - Berardicurti, Onorina

AU - Pantano, Ilenia

AU - Liakouli, Vasiliki

AU - Alvaro, Saverio

AU - Alunno, Alessia

AU - Manzo, Antonio

AU - Ciccia, Francesco

AU - Gerli, Roberto

AU - Triolo, Giovanni

AU - Giacomelli, Roberto

PY - 2013/10/30

Y1 - 2013/10/30

N2 - Introduction: Primary Sjögren's syndrome (pSS) is an autoimmune disorder affecting exocrine glands; however, a subgroup of pSS patients experience systemic extra-glandular involvement leading to a worsening of disease prognosis. Current therapeutic options are mainly empiric and often translated by other autoimmune diseases. In the last few years growing evidence suggests that B-cell depletion by rituximab (RTX) is effective also in pSS. Patients with early active disease appear to be those who could benefit the most from RTX. The aim of this study was to investigate the efficacy and safety of RTX in comparison to disease modifying anti-rheumatic drugs (DMARDs) in early active pSS patients. Methods: Forty-one patients with early pSS and active disease (EULAR Sjogren's syndrome disease activity index, ESSDAI ≥ 6) were enrolled in the study. Patients were treated with either RTX or DMARDs in two different Rheumatology centers and followed up for 120 weeks. Clinical assessment was performed by ESSDAI every 12 weeks up to week 120 and by self-reported global disease activity pain, sicca symptoms and fatigue on visual analogic scales, unstimulated saliva flow and Schirmer's I test at week 12, 24, 48, 72, 96, and 120. Laboratory assessment was performed every 12 weeks to week 120. Two labial minor salivary gland (MSG) biopsies were obtained from all patients at the time of inclusion in the study and at week 120.Results: Our study demonstrated that RTX treatment results in a faster and more pronounced decrease of ESSDAI and other clinical parameters compared to DMARDs treatment. No adverse events were reported in the two groups. We also observed that RTX is able to reduce glandular infiltrate, interfere with B/T compartmentalization and consequently with the formation of ectopic lymphoid structures and germinal center-like structures in pSS-MSGs. Conclusions: To our knowledge, this is the first study performed in a large cohort of early active pSS patients for a period of 120 weeks. We showed that RTX is a safe and effective agent to be employed in pSS patients with systemic, extra-glandular involvement. Furthermore, our data on pSS-MSGs provide additional biological basis to employ RTX in this disease.

AB - Introduction: Primary Sjögren's syndrome (pSS) is an autoimmune disorder affecting exocrine glands; however, a subgroup of pSS patients experience systemic extra-glandular involvement leading to a worsening of disease prognosis. Current therapeutic options are mainly empiric and often translated by other autoimmune diseases. In the last few years growing evidence suggests that B-cell depletion by rituximab (RTX) is effective also in pSS. Patients with early active disease appear to be those who could benefit the most from RTX. The aim of this study was to investigate the efficacy and safety of RTX in comparison to disease modifying anti-rheumatic drugs (DMARDs) in early active pSS patients. Methods: Forty-one patients with early pSS and active disease (EULAR Sjogren's syndrome disease activity index, ESSDAI ≥ 6) were enrolled in the study. Patients were treated with either RTX or DMARDs in two different Rheumatology centers and followed up for 120 weeks. Clinical assessment was performed by ESSDAI every 12 weeks up to week 120 and by self-reported global disease activity pain, sicca symptoms and fatigue on visual analogic scales, unstimulated saliva flow and Schirmer's I test at week 12, 24, 48, 72, 96, and 120. Laboratory assessment was performed every 12 weeks to week 120. Two labial minor salivary gland (MSG) biopsies were obtained from all patients at the time of inclusion in the study and at week 120.Results: Our study demonstrated that RTX treatment results in a faster and more pronounced decrease of ESSDAI and other clinical parameters compared to DMARDs treatment. No adverse events were reported in the two groups. We also observed that RTX is able to reduce glandular infiltrate, interfere with B/T compartmentalization and consequently with the formation of ectopic lymphoid structures and germinal center-like structures in pSS-MSGs. Conclusions: To our knowledge, this is the first study performed in a large cohort of early active pSS patients for a period of 120 weeks. We showed that RTX is a safe and effective agent to be employed in pSS patients with systemic, extra-glandular involvement. Furthermore, our data on pSS-MSGs provide additional biological basis to employ RTX in this disease.

UR - http://www.scopus.com/inward/record.url?scp=84886552636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886552636&partnerID=8YFLogxK

U2 - 10.1186/ar4359

DO - 10.1186/ar4359

M3 - Article

VL - 15

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

SN - 1478-6354

IS - 5

M1 - R172

ER -